Miniatura

Fitxers

864890.pdf (990.11 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-06-01

Llicència de publicació

cc by-nc (c) Jolly, Sanjit S. et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/225780

SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.amjcard.2024.02.021

Resum

Our objective was to evaluate the clinical effectiveness of the SYNERGY stent (Boston Scientific Corporation, Marlborough, Massachusetts) in patients with ST-elevation myocardial infarction (STEMI). The only drug-eluting stent approved for treatment of STEMI by the Food and Drug Administration is the Taxus stent (Boston Scientific) which is no longer commercially available, so further data are needed. The CLEAR (Colchicine and spironolactone in patients with myocardial infarction) SYNERGY stent registry was embedded into a larger randomized trial of patients with STEMI (n = 7,000), comparing colchicine versus placebo and spironolactone versus placebo. The primary outcome for the SYNERGY stent registry is major adverse cardiac events (MACE) as defined by cardiovascular death, recurrent MI, or unplanned ischemia-driven target vessel revascularization within 12 months. We estimated a MACE rate of 6.3% at 12 months after primary percutaneous coronary intervention for STEMI based on the Thrombectomy vs percutaneous coronary intervention alone in STEMI (TOTAL) trial. Success was defined as upper bound of confidence interval (CI) to be less than the performance goal of 9.45%. Overall, 733 patients were enrolled from 8 countries with a mean age 60 years, 19.4% diabetes mellitus, 41.3% anterior MI, and median door-to-balloon time of 72 minutes. The MACE rate was 4.8% (95% CI 3.2 to 6.3%) at 12 months which met the success criteria against performance goal of 9.45%. The rates of cardiovascular death, recurrent MI, or target vessel revascularization were 2.7%, 1.9%, 1.0%, respectively. The rates of acute definite stent thrombosis were 0.3%, subacute 0.4%, late 0.4%, and cumulative stent thrombosis of 1.1% at 12 months. In conclusion, the SYNERGY stent in STEMI performed well and was successful compared with the performance goal based on previous trials.

Matèries

Infart de miocardi, Cardiologia

Matèries (anglès)

Myocardial infarction, Cardiology

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

JOLLY, Sanjit s, LEE, Shun fu, MIAN, Rajibul, KEDEV, Sasko, LAVI, Shahar, MORENO, Raul, MONTALESCOT, Gilles, HILLANI, Ali, HENRY, Timothy d, ASANI, Valon, STOREY, Robert f, SILVAIN, Johanne, SPRATT, James c s, D'ENTREMONT, Marc-andré, STANKOVIC, Goran, ZAFIROVSKA, Biljana, NATARAJAN, Madhu k, SABATE TENAS, Manuel, SHREENIVAS, Satya, PINILLA-ECHEVERRI, Natalia, SHETH, Tej, ALTISENT, Omar abdul-jawad, RIBAS, Núria, SKURIAT, Elizabeth, TYRWHITT, Jessica, MEHTA, Shamir r. SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry. _American Journal of Cardiology_. 2024. Vol. 220, núm. 111-117. [consulta: 23 de gener de 2026]. ISSN: 0002-9149. [Disponible a: https://hdl.handle.net/2445/225780]

Exportar metadades

JSON - METS

Compartir registre